|
|
Volumn 95, Issue 3, 2002, Pages 277-283
|
|
Recombinant Interleukin-2 (aldesleukin) for oncology and HIV disease and recombinant protein treatment (Fabrazyme) for Fabry's disease (No. 14 in a series of articles to promote a better understanding of the use of genetic engineering)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AGALSIDASE BETA;
ALPHA GALACTOSIDASE;
GAMMA INTERFERON;
IMMUNOGLOBULIN;
INTERLEUKIN 10;
INTERLEUKIN 2;
INTERLEUKIN 4;
INTERLEUKIN 5;
RECOMBINANT INTERLEUKIN 2;
RECOMBINANT PROTEIN;
UNCLASSIFIED DRUG;
CAPILLARY LEAK SYNDROME;
CELL DIFFERENTIATION;
CELL SURVIVAL;
CLINICAL FEATURE;
CLINICAL TRIAL;
CYTOKINE PRODUCTION;
DRUG APPROVAL;
DRUG EFFECT;
DRUG SAFETY;
FABRY DISEASE;
FLU LIKE SYNDROME;
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS 1;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
IMMUNOGLOBULIN PRODUCTION;
IMMUNOMODULATION;
KIDNEY CARCINOMA;
LYMPHOCYTE ACTIVATION;
LYMPHOCYTE PROLIFERATION;
MELANOMA;
NONHUMAN;
PRIORITY JOURNAL;
REVIEW;
T LYMPHOCYTE;
HUMAN IMMUNODEFICIENCY VIRUS;
HUMAN IMMUNODEFICIENCY VIRUS 1;
|
|
EID: 0037161638
PISSN: 01681656
EISSN: None
Source Type: Journal
DOI: 10.1016/S0168-1656(02)00019-6 Document Type: Article |
|
Times cited : (12)
|
|
References (5)
|
